Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023004 | 1.00 | ACE (0.54) | ACEPPARAPTPN1MMECPA1 | |
| SCHEMBL4850339 | 0.92 | TACR1 (0.53) | ACEPPARASCN9ACTSSCTSB | |
| SCHEMBL1023115 | 0.92 | TACR1 (0.53) | ACEPPARASCN9ACTSSCTSB | |
| SCHEMBL1023510 | 0.87 | MME (0.51) | ACEPPARAMMECPA1ACE2 | |
| SCHEMBL1023509 | 0.87 | MME (0.51) | ACEPPARAMMECPA1ACE2 | |
| SCHEMBL2584592 | 0.87 | ACE (0.61) | ACEPPARAPTPN1MMECPA1 | |
| SCHEMBL14497709 | 0.87 | CTSS (0.45) | ACEMMECPA1ACE2CTSS | |
| SCHEMBL5159314 | 0.87 | CTSS (0.49) | ACEPTPN1CTSSCTSBCTSK | |
| SCHEMBL14497707 | 0.87 | CTSS (0.49) | PTPN1CTSSCTSBCTSKCTSL | |
| SCHEMBL14497790 | 0.86 | CTSB (0.47) | ACEPTPN1MMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| US-20070129288-A1 | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2007-06-07 | — | — | US | disclosed |
| EP-1515983-B1 | ANTIBACTERIAL AMIDE MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-20060258571-A1 | Antibacterial ester macrocycles | AICURIS GMBH & CO. KG (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20050256037-A1 | Antibacterial amide macrocyles | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005100380-A1 | ANTIBACTERIAL AMIDE MACROCYCLES II | AICURIS GMBH & CO.KG (DE) | 2005-10-27 | — | — | WO | disclosed |
| EP-1526896-A1 | ANTIBACTERIAL ESTER MACROCYCLES | Bayer HealthCare AG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005033129-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2005-04-14 | — | — | WO | disclosed |
| EP-1515983-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004012816-A1 | ANTIBACTERIAL ESTER MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003106480-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129288-A1 | Antibacterial amide macrocycles | AADAC, AAAS, MRPL21 | ACE 68/4885PPARA 343/4885PTPN1 3958/4885 |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | ACE 23/4885PPARA 169/4885PTPN1 4036/4885 |
| US-20050256037-A1 | Antibacterial amide macrocyles | AADAC, PAM, NOD2 | ACE 45/4885PPARA 80/4885PTPN1 4282/4885 |
| US-20060258571-A1 | Antibacterial ester macrocycles | TECR, MRPL21, CYP51A1 | ACE 319/4885PPARA 149/4885PTPN1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.